Ignite Creation Date:
2024-05-06 @ 7:40 AM
Last Modification Date:
2024-10-26 @ 11:50 AM
Study NCT ID:
NCT02572596
Status:
UNKNOWN
Last Update Posted:
2017-02-09
First Post:
2015-09-17
Brief Title:
Comparing Intermediate-dose CTX G-CSF Plus or Not rhTPO for PB CD34 Cells Mobilization in MM Patients
Sponsor:
Wang Guorong
Organization:
Beijing Chao Yang Hospital
Study Overview
Official Title:
A Prospective Control Study of Comparing Intermediate-dose CyclophosphamideID-CTX and G-CSF Plus or Not Recombinant Human Thrombopoietin rhTPO for PBSC Mobilization in Patients With Multiple Myeloma
Status:
UNKNOWN
Status Verified Date:
2017-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Comparing intermediate-dose CTX ID-CTXand G-CSF with rhTPO or without for peripheral blood stem cell mobilization in patients with multiple myeloma try to find out whether rhTPO combined to ID-CTX G-CSF could improve the results of peripheral blood stem cell mobilization
Detailed Description:
The purpose of this study is to try to find out whether rhTPO combined to ID-CTX G-CSF could improve the results of peripheral blood stem cell mobilization Comparing ID-CTX and G-CSF plus rhTPO or not for peripheral blood stem cell mobilization in patients with multiple myeloma rhTPO15000Ud were given from day 57 after chemotherapy until the stem cell collection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None